Thus, our and other studies suggest that the pharmacological inhibition of JNK pathway could represent an effective potential adjuvant to other—already in use—SMN-dependent therapies for treating SMA disease (like the antisense oligonucleotides nusinersen, Biogen) [129] which constitute a very promising strategy for SMA, but still have some limitations [130]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.